Categories
Archives
- 2026
- 2025
- 2024
- 2023
Oct
16
UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
Oct
12
UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis
Oct
09
UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia
Sep
30
Inside a PowerHouSe: Conversations, Connection & Learning at the 2026 UCB HS Summit
Sep
29
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
Sep
09
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
Aug
31
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing
Aug
16
Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award
Aug
05
Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
